Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...1718192021222324252627...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  ANGIOGRAPHIC RISK FACTORS FOR RECURRENCE OF MACULAR EDEMA ASSOCIATED WITH BRANCH RETINAL VEIN OCCLUSION. (Pubmed Central) -  Dec 16, 2021   
    The parafoveal VDI may adequately represent the degree of congestion associated with branch retinal vein occlusion. Particularly, the VDI in the temporal sector may be a good predictor of future retinal thickening in the corresponding parafovea and the fovea and the number of ranibizumab injections.
  • ||||||||||  LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Anti-Vascular Endothelial Growth Factor Dosing and Expected Acuity Outcome at 1 Year. (Pubmed Central) -  Dec 16, 2021   
    There seems to be a predictable, mathematically defined relationship between dose frequency and visual acuity change at 1 year in neovascular age-related macular degeneration. The performance of current treatment efforts, as suggested by reported series and Medicare claims data, seems to be substandard.
  • ||||||||||  LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection. (Pubmed Central) -  Dec 16, 2021   
    Non-infectious IOI following intravitreal anti-VEGF injection typically occurs without pain, conjunctival injection, hypopyon, or fibrin and responds well to topical steroid therapy. Visual acuity returns to baseline levels within weeks according to the severity of inflammation.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Management of retinopathy of prematurity (ROP) in a Polish cohort of infants. (Pubmed Central) -  Dec 16, 2021   
    As the first line of treatment, 115 infants (226 eyes, 64.6%) underwent laser photocoagulation (LP); 61 infants (120 eyes, 34.3%) received intravitreal ranibizumab injections (IVR); and 2 infants (4 eyes, 0.6%) were treated simultaneously with LP and IVR...The incidence of ROP, ROP requiring treatment, and reoccurrence rates are higher in the Polish population than in Western Europe and the USA. The identified treatment patterns find increasing use of anti-VEGF agents.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Effect of intravitreal ranibizumab and aflibercept injections on retinal nerve fiber layer thickness. (Pubmed Central) -  Dec 16, 2021   
    Multiple IVR and IVA injections are apparently safe considering peripapillary RNFL damage in patients with exudative AMD. The decreased RNFL thickness of the global sector was presumably due to anatomical improvement of macular lesions.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Review, Journal:  Screening for retinopathy of prematurity-the most important changes in the new German guidelines 2020 (Pubmed Central) -  Dec 16, 2021   
    The number of HRF in the outer retina, in addition to other baseline OCT biomarkers, could be used to predict the treatment response in DME after anti-VEGF treatment. The guideline recommendations enable a reliable identification of infants at risk for ROP for screening inclusion and a timely detection of advanced disease stages for treatment initiation, thus preventing blindness from ROP.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  The Eye in Internal Medicine: Diabetic retinopathy (Pubmed Central) -  Dec 16, 2021   
    The same accounts for the collaboration of opthalmologists, general practioners, and diabetologists. Good control of diabetes and blood pressure is still important.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Outcomes of combined treatments in patients with retinal arterial macroaneurysm. (Pubmed Central) -  Dec 16, 2021   
    To evaluate the outcome of the combined approach between intravitreal ranibizumab (IVR) and focal laser photocoagulation (FLP) in the treatment of symptomatic retinal arterial macroaneurysm (RAM)...No ocular and/or systemic side effects were evident, and no recrudescence of RAM was seen within the 6 months of follow-up. The combined treatment of IVRs and FLPs was successful in the management of symptomatic RAM.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  INTRAOCULAR JARISCH-HERXHEIMER REACTION IN LEMIERRE SYNDROME. (Pubmed Central) -  Dec 2, 2021   
    However, more high-quality randomized controlled trials with longer follow-up using standard methods are still needed to verify the correlation. To the best of our knowledge, this is the first reported case of an isolated intraocular Jarisch-Herxheimer reaction induced by Lemierre syndrome antibiotherapy and successfully treated with a single intravitreal injection of ranibizumab.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  Anti-VEGF Therapy in Myopic CNV. (Pubmed Central) -  Dec 1, 2021   
    Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is recommended as the first-line treatment option for mCNV. Prompt treatment of active mCNV with intravitreal anti-VEGF therapy has been demonstrated effective in terms of visual outcome improvements reducing the occurrence of late-stage complications.
  • ||||||||||  Beovu (brolucizumab-dbll) / Novartis, Avastin (bevacizumab) / Roche
    Review, Journal, Adverse events:  Side Effects of Brolucizumab. (Pubmed Central) -  Nov 30, 2021   
    A PubMed and Scopus search was performed and all article types were included. In the present article, we have reviewed the reported side effects of brolucizumab.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Increased levels of cytokines in the aqueous humor correlate with the severity of diabetic retinopathy. (Pubmed Central) -  Nov 29, 2021   
    This study suggests that TGF-β, ICAM-1, IL-10, VEGF, and VCAM-1 may play a role in the progression of diabetic retinopathy, especially TGF-β, which may plays a significant role in NVG-PDR. These cytokines potentially may be used as biomarkers to predict the progress of diabetic retinopathy, contribute to the choice of treatment options and/or monitor treatment responses.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients. (Pubmed Central) -  Nov 29, 2021   
    We also included genetic variants in the VEGFA gene. Based on our results, ARMS2 (rs10490924) and CFH (rs1061170) are associated with response to ranibizumab in high myopia patients; and, included VEGFA genetic polymorphisms are not associated with ranibizumab response in our population but might be related to a higher risk of CNV.